ASND: overvalued.
Figures as of the 2026-10-19 close.
Ascendis Pharma A/S carries debt worth 0.31 times its shareholders' equity, a light load. Its current assets cover its short-term liabilities 2.99 times.
We do not compute an Altman Z-Score for ASND: its latest annual report lacks a figure the formula needs, and we would rather say so than estimate it.
It scores 6 out of 9 on the Piotroski F-Score, which checks whether profitability, leverage and efficiency improved from one annual report to the next. Seven or more is strong; three or fewer is weak. Which tests it passes, and the red flags in its accounts, are in the full analysis.